[The early phase of vincristine-induced neuropathy. Electrophysiological evidence of a "dying-back" phenomenon (author's transl)].
Electrophysiological exploration was carried out in 12 patients before and during administration of vincristine sulphate 1,4 mg/m2 body surface area. The patients had stage III or IV lymphoreticulosarcoma and received one injection of vincristine weekly for 6 weeks. Compared with pretreatment findings, (1) motor and sensory conduction velocity, as well as delay in triceps surae H reflex remained unchanged; (2) sensory nerve amplitude and density of distal muscle electromyographic recordings rapidly decreased; (3) the amplitude of distal tendinous reflexes rapidly diminished, whereas that of the H reflex remained stable. These results being similar to those observed in experimental acrylamide toxicity, where a "dying back" hemopathy has been demonstrated, it is suggested that the neuropathy induced by vincristine in man is of the same type.
D000178:Acrylamides / Q000506:poisoning; D000328:Adult; D001369:Axons / Q000187:drug effects*; D004594:Electrophysiology; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000503:physiopathology; D012183:Retrograde Degeneration / Q000187:drug effects; D013997:Time Factors; D014750:Vincristine / Q000009:adverse effects*
D000178:Acrylamides; D014750:Vincristine
Phase précoce de la neuropathie à la vincristine. Arguments électrophysiologiques en faveur d'une axonopathie distale rétrograde.